Altos Labs
AUDIT: Altos Labs: Senolytic Insolvency, and the $3 Billion Biological Debt
A forensic audit of Altos Labs' $3B longevity pivot. Explore the biological reality of epigenetic reprogramming, senolytic insolvency, and FDA roadblocks.
Senolytic Insolvency